Company intelligence

Akari Therapeutics

Biotech

Recent changes

  1. Jun 26, 2026Akari Therapeutics Files an S-1/A to Fund Its TROP2 Cancer Drug Toward the Clinic Pulse story
  2. Jun 3, 2026Raised $1.8M SEC EDGAR Form D

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Jun 3, 2026funding round$1.8M—
SEC EDGAR Form D

Latest Pulse

  1. Akari Therapeutics Files an S-1/A to Fund Its TROP2 Cancer Drug Toward the ClinicOncology biotech Akari Therapeutics (Nasdaq: AKTX) filed a Form S-1/A with the SEC to register capital as it advances AKTX-101, a TROP2-targeting antibody-drug conjugate built on its proprietary PH1 payload platform. The filing adds another clinical-stage cancer name to a 2026 capital-markets pipeline that biotech is increasingly populating alongside AI and chips.→

Coverage Timeline

newest first
  1. IPOAkari Therapeutics Files an S-1/A to Fund Its TROP2 Cancer Drug Toward the Clinic→

All Coverage

IPO

Akari Therapeutics Files an S-1/A to Fund Its TROP2 Cancer Drug Toward the Clinic

Related Companies

Same sector
Attovia TherapeuticsApnimedBraveheart BioLatigo BiotherapeuticsScribe Therapeutics
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction